Market Overview

UPDATE: Credit Suisse Initiates Infinity Pharmaceuticals at Outperform on Risk/Reward

Related INFI
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma
3 Partnerships Pushing The Pharmaceutical Sector Forward

Credit Suisse initiated coverage on Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) with a Outperform rating and a $42.00 price target.

Credit Suisse commented, "We believe that the next steps in the development of IPI-145 are lower risk than typical for a drug at its stage, and expect IPI-145 to emerge as a best-in-class PI3K inhibitor. We also view the target markets as able to support several multibillion dollar drugs, and expect that IPI-145 could capture a meaningful share. While higher risk, earlier stage, and less investible than its larger pier PCYC, we believe that risk/reward for INFI remains favorable."

Infinity Pharmaceuticals closed at $32.93 on Monday.

Latest Ratings for INFI

DateFirmActionFromTo
Oct 2014Stifel NicolausInitiates Coverage onHold
Sep 2014JMP SecuritiesUpgradesMarket PerformMarket Outperform
Sep 2014JefferiesMaintainsBuy

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters